Between-patient differences in the renal response to renin-angiotensin system intervention: Clue to optimising renoprotective therapy?

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 3, Issue 4, 2002, Pages 205-213

  Laverman, Gozewijn D ^a,c   de Zeeuw, Dick ^a,b   Navis, Gerjan ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

Patient factors; RAAS blockade; Renoprotection; Sodium status; Therapy response

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; INDOMETACIN; LISINOPRIL; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; RAMIPRIL;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; DIET RESTRICTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FOOD DRUG INTERACTION; GENETIC HETEROGENEITY; GLOMERULUS FILTRATION RATE; HEREDITY; HUMAN; HYPERTENSION; INDIVIDUALITY; INSULIN RESISTANCE; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FAILURE; NONHUMAN; NUTRITIONAL PARAMETERS; OBESITY; PROTEIN INTAKE; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM INTAKE;

EID: 0036986237     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2002.042     Document Type: Review

References (67)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.
2. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87.
3. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-45.
4. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
5. Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
6. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008-13.
7. Apperloo AJ, De Zeeuw D, De Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997;51:793-7.
8. Apperloo AJ, De Zeeuw D, De Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 1994;45(suppl):S174-S178.
9. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994;37:511-16.
10. Eddy AA, Giachelli CM. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 1995;47:1546-57.
11. Zoja C, Benigni A, Remuzzi G. Protein overload activates proximal tubular cells to release vasoactive and inflammatory mediators. Exp Nephrol 1999;7:420-8.
12. Abbate M, Zoja C, Rottoli D et al. Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates pro. J Am Soc Nephrol 1999;10:804-13.
13. Jafar TH, Stark PC, Schmid CH et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60:1131-40.
14. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001;357: 1601-08.
15. Praga M. Slowing the progression of renal failure. Kidney Int 2002;61(suppl 80):18-22.
16. De Jong PE, Navis G, De Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 1999;354:352-3.
17. Bos H, Andersen S, Rossing P et al. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int 2000;57:S32-S37.
18. Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000;35:1155-65.
19. Ruggenenti P, Remuzzi G. Nephropathy in NIDDM patients, predictors of outcome, chapter 20. In: Mogensen CE (eds.). The kidney and hypertension in diabetes mellitus, 1 edition. Boston-Dordrecht-London: Kluwer Academic Publishers, 2000;237-46.
20. Lufft V, Kliem V, Hamkens A et al. Antiproteinuric efficacy of fosinopril after renal transplantation is determined by the extent of vascular and tubulointerstitial damage. Clin Transplant 1998;12:409-15.
21. Kramer AB, Laverman GD, van Goor H, Navis GJ. Interindividual differences in antiproteinuric response to ACEi in established adriamycin nephrosis are predicted by pre-treatment renal damage. J Pathol 2003, provisionally accepted for publication.
22. Perico N, Amuchastegui SC, Colosio V, Sonzogni G, Bertani T, Remuzzi G. Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. J Am Soc Nephrol 1994;5:1139-46.
23. Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 2001;12: 2832-7.
24. Bos H, Henning RH, De Jong PE, De Zeeuw D, Navis G. Do severe systemic sequelae of proteinuria modulate the antiproteinuric response to chronic ACE inhibition? Nephrol Dial Transplant 2002;17:793-7.
25. Navis G, de Jong P, Donker AJ, van der Hem GK, De Zeeuw D. Diuretic effects of angiotensin-converting enzyme inhibition: comparison of low and liberal sodium diet in hypertensive patients. J Cardiovasc Pharmacol 1987;9:743-8.
26. Navis G, De Jong PE, Donker AJ, van der Hem GK, De Zeeuw D. Moderate sodium restriction in hypertensive subjects: renal effects of ACE-inhibition. Kidney Int 1987;31:815-19.
27. Heeg JE, De Jong PE, van der Hem GK, De Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989;36:272-9.
28. Buter H, Hemmelder MH, Navis G, De Jong PE, De Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998;13:1682-5.
29. Gansevoort RT, De Zeeuw D, De Jong PE. Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. Nephrol Dial Transplant 1995;10:497-504.
30. Praga M. Obesity - a neglected culprit in renal disease. Nephrol Dial Transplant 2002;17:1157-9.
31. Praga M, Hernandez E, Morales E et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001;16:1790-8.
32. Price DA, Lansang MC, Osei SY, Fisher ND, Laffel LM, Hollenberg NK. Type 2 diabetes, obesity, and the renal response to blocking the renin system with irbesartan. Diabet Med 2002;19:858-61.
33. Rocchini AP. Obesity hypertension. Am J Hypertens 2002; 15:50S-52S.
34. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5.
35. Wolf G, Hamann A, Han DC et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int 1999;56:860-72.
36. Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis 2002;39:1-11.
37. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue reninangiotensin system: relationship to obesity and hypertension. J Hypertens 2002;20:965-73.
38. Osei SY, Price DA, Fisher ND, Porter L, Laffel LM, Hollenberg NK. Hyperglycemia and angiotensin-mediated control of the renal circulation in healthy humans. Hypertension 1999;33:559-64.
39. Osei SY, Price DA, Laffel LM, Lansang MC, Hollenberg NK. Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans. Hypertension 2000;36:122-6.
40. Lansang MC, Price DA, Laffel LM et al. Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus. Kidney Int 2001;59:1432-8.
41. Laffel LM, Price DA, Hollenberg NK. Glycemic control and plasma renin activity predict renal hemodynamic response to captopril in normotensive normoalbuminuric patients with IDDM. (abstract) J Am Soc Nephrol 1998;9:117A.
42. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001;41:101-21.
43. Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 1995;26:124-30.
44. Hollenberg NK, Anzalone DA, Falkner B et al. Familial factors in the antihypertensive response to lisinopril. Am J Hypertens 2001;14:218-23.
45. Barlassina C, Schork NJ, Manunta P etal. Synergistic effect of alpha-adducin and ACE genes causes blood pressure changes with body sodium and volume expansion. Kidney Int 2000;57:1083-90.
46. Jordan J, Tank J, Shannon JR et al. Baroreflex buffering and susceptibility to vasoactive drugs. Circulation 2002;105:1459-64.
47. Tank J, Jordan J, Diedrich A et al. Genetic influences on baroreflex function in normal twins. Hypertension 2001;37: 907-10.
48. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6.
49. Mayer G. ACE genotype and ACE inhibitor response in kidney disease: a perspective. Am J Kidney Dis 2002;40:227-35.
50. Ruggenenti P, Perna A, Zoccali C et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). J Am Soc Nephrol 2000;11:88-96.
51. Der Kleij FG, De Jong PE, Henning RH, De Zeeuw D, Navis G: Enhanced responses of blood pressure, renal function, and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake. J Am Soc Nephrol 2002;13:1025-33.
52. van der Kleij FG, Schmidt A, Navis GJ et al. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. Kidney Int 1997;63(suppl):S23-S26.
53. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001;37:739-43.
54. Praga M, Hernandez E, Andres A, Leon M, Ruilope LM, Rodicio JL. Effects of body-weight loss and captopril treatment on proteinuria associated with obesity. Nephron 1995;70:35-41.
55. van Paassen P, De Zeeuw D, Navis G, De Jong PE. Does the renin-angiotensin system determine the renal and systemic hemodynamic response to sodium in patients with essential hypertension? Hypertension 1996;27:202-08.
56. van Paassen P, Navis GJ, De Jong PE, De Zeeuw D. Pretreatment renal vascular tone predicts the effect of specific renin inhibition on natriuresis in essential hypertension. Eur J Clin Invest 1999;29:1019-26.
57. Bos H, Henning RH, De Boer E et al. Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis. Kidney Int 2002;61:473-80.
58. Haas M, Leko-Mohr Z, Erler C, Mayer G. Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy. Am J Kidney Dis 2002;40:458-63.
59. Laverman GD, Andersen S, Rossing P, Navis GJ, De Zeeuw D, Parving HH. Dose-dependent reduction of proteinuria by losartan does not require reduction of blood pressure. (abstract) J Am Soc Nephrol 2002;13:265A.
60. Russo D, Pisani A, Balletta MM et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999;33:851-6.
61. Russo D, Minutolo R, Pisani A et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18-25.
62. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.
63. Agarwal R. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001;59:2282-9.
64. Laverman GD, Navis G, Henning RH, De Jong PE, De Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002;62:1020-5.
65. Ruggenenti P, Brenner BM, Remuzzi G. Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. Nephron 2001;88:254-9.
66. Zoja C, Corna D, Rottoli D et al. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 2002;61:1635-45.
67. Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A. Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 1999;10:1542-9.